Pediatrics Doctors in Long Island City, NY Accepting Medicare

27 Pediatrics doctors found. Showing 21 - 27

Dr. Marian Larkin, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4209 28th St # Cn-25, Long Island City, NY 11101 Phone: 646-385-2431

Arti Jaiswal, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3611 21st St, Long Island City, NY 11106 Phone: 718-482-7772    Fax: 718-482-9648

Beena Iype, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3030 47th Ave Fl 7, Long Island City, NY 11101 Phone: 000-000-0000

Dr. Amanda Thomas, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4727 Vernon Blvd, Long Island City, NY 11101 Phone: 212-226-7666

Shideh Shafinoori Maybody, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3016 30th Dr, Long Island City, NY 11102 Phone: 718-626-0670    Fax: 718-626-0694

Krishika Acharya Graham, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4209 28th St, Long Island City, NY 11101 Phone: 646-331-0473

Leena Navin Patel, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4209 28th St # Cn-65, Long Island City, NY 11101 Phone: 408-887-5562

News Archive

Lifting the lid on coronavirus flatulence

The highly infectious virus is spread via aerosols (droplets of saliva or nasal discharge spread by coughing or sneezing by the infected person with the mouth uncovered). New speculation reveals that it could spread via fecal matter and even via farts or flatulence. Researchers believe that there is some truth to this speculation.

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.

Odds of experiencing sexual aggression vastly greater when college women binge drink

According to researchers at the University at Buffalo's Research Institute on Addictions (RIA), the odds of 18- and 19-year-old college women experiencing sexual aggression are 19 times greater when they binge drink than when they don't drink.

FDA approves Plavix for STEMI heart attacks

The Food and Drug Administration (FDA) today approved the use of Plavix (clopidogrel bisulfate) for patients who have had a type of heart attack called acute ST-segment elevation myocardial infarction (STEMI), who are not going to have coronary artery repair (angioplasty).

Read more Medical News

› Verified 8 days ago

• 1
• 2(current)